How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

445 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. An update to the Greig Health Record: Preventive health care visits for children and adolescents aged 6 to 17 years ? Technical report

a helpful statement for guidance in such cases. Template use In the , checklist templates are divided into three age ranges: , and years (inclusive). Section headings include: Weight, Height and BMI, Psychosocial history and Development, Nutrition, Education & Advice, Specific Concerns, Examination, Assessment, Immunization, and Medications . The checklist tables are divided arbitrarily into early, middle and late age groupings, but it is important to remember that children develop at different rates (...) sexually active. None of these organizations recommend HPV screening for females under age 21 years of age. Vaccination against HPV does not eliminate the necessity for screening. Further research is needed into the effectiveness of HPV vaccines over the longer term. For details on HPV vaccines, see Immunizations and TB Screening, below. Sexually transmitted infection (STI) screening STI testing is recommended in all sexually active women under 25 years of age, at least annually; there is good evidence

2016 Canadian Paediatric Society

82. HTA of HPV testing for cervical cancer screening

equivalent was run from 2011 until 2014. HPV 6 and HPV 11 are associated with approximately 90% of anogenital wart cases. HPV 16 and HPV 18 are associated with approximately 70% of squamous cell carcinomas (the most common histological type of cervical cancer globally and in Ireland). Cervical screening of women who have been vaccinated against HPV is recommended because the current quadrivalent vaccine does not protect against cervical cancers caused by other high-risk HPV types. The first cohort

2017 Health Information and Quality Authority

83. WHO guidelines for the treatment of Genital Herpes Simplex Virus

of genital herpes simplex virus 17 4.1 First clinical episode of genital HSV infection 17 Recommendation 1 17 Recommendation 2 17WHO GUIDELINES FOR THE TREATMENT OF GENITAL HERPES SIMPLEX VIRUS ii 4.2 Recurrent clinical episode of genital HSV infection (episodic therapy) 18 Recommendation 3 18 Recommendation 4 18 4.3 Recurrent clinical episodes of genital HSV infection that are frequent, severe or cause distress (suppressive therapy) 20 Recommendation 5 20 Recommendation 6 20 5. Research implications 22 (...) . ACKNOWLEDGEMENTSWHO GUIDELINES FOR THE TREATMENT OF GENITAL HERPES SIMPLEX VIRUS iv AIDS acquired immune deficiency syndrome AMR antimicrobial resistance CI confidence interval DOI declaration of interests GDG Guideline Development Group GRADE Grading of Recommendations Assessment, Development and Evaluation GUD genital ulcer disease HIV human immunodeficiency virus HPV human papillomavirus HRP UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction

2016 World Health Organisation Guidelines

84. Cervical Cancer: ESMO Clinical Practice Guidelines

and the brain. Managementoflocal/locoregionaldisease (Figure1) Primarytreatment Surgery. Surgical therapy in cervical cancer is adapted to the stage of disease according to FIGO and TNM classi?cation (Table 2). Microinvasive cervical cancer (stage IA1) without LVSI can be managed with conisation or simple trachelectomy to preserve Clinical Practice Guidelines Annals of Oncology iv74 | Marth et al. Volume 28 | Supplement 4 | August 2017fertility [I, B] [18]. Simple hysterectomy can be offered if the patient (...) of these issues by studying the use of a dose- dense schedule, incorporating a taxane and eliminating the interval between induction chemotherapy and RT. Lymph node staging and radiotherapy. In patients with LACC, RT treatment planning relies on accurate staging information. Pelvic MRI and clinical examination is essential to determine the local extent of the tumour for both external beam RT and brachy- therapy planning. Information on para-aortic nodal status is also essential for treatment planning

2017 European Society for Medical Oncology

85. WHO guidelines for the treatment of Treponema pallidum (syphilis)

.Syphilis – drug therapy. 2.Treponema pallidum. 3.Sexually Transmitted Diseases. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154980 6 (NLM classification: WC 170) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int (...) ) Methodologist: Nancy Santesso. ACKNOWLEDGEMENTSWHO GUIDELINES FOR THE TREATMENT OF TREPONEMA PALLIDUM (SYPHILIS) iv ABBREVIATIONS AND ACRONYMS AIDS acquired immune deficiency syndrome AMR antimicrobial resistance CI confidence interval DFA direct fluorescent antibody DNA deoxyribonucleic acid DOI declaration of interests FTA-ABS fluorescent treponemal antibody absorbed GDG Guideline Development Group GRADE Grading of Recommendations Assessment, Development and Evaluation GUD genital ulcer disease HIV human

2016 World Health Organisation Guidelines

86. WHO guidelines for the treatment of Neisseria gonorrhoeae

WHO guidelines for the treatment of Neisseria gonorrhoeae WHO GUIDELINES FOR THE Treatment of Neisseria gonorrhoeae WHO GUIDELINES FOR THE Treatment of Neisseria gonorrhoeae WHO Library Cataloguing-in-Publication Data WHO guidelines for the treatment of Neisseria gonorrhoeae. Contents: Web annex D: Evidence profiles and evidence-to-decision framework -- Web annex E: Systematic reviews -- Web annex F: Summary of conflicts of interest 1.Neisseria gonorrhoeae - drug therapy. 2.Gonorrhea - drug (...) therapy. 3.Drug Resistance, Microbial. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154969 1 (NLM classification: WC 150) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce

2016 World Health Organisation Guidelines

87. Gynecologic Care for Women and Adolescents With Human Immunodeficiency Virus

have more and larger warts and higher risk of recurrences after treatment. A biopsy should be taken of warts that fail to respond to standard therapy to ensure vulvar intraepithelial neoplasia or cancer is not present ( ). Women infected with HIV have higher rates of vaginal, vulvar, and perianal neoplasia ( , ) and high-grade anal intraepithelial neoplasia and anal cancer (11) compared with the general population. Women infected with HIV who undergo assessment for cervical or vaginal cytologic (...) , such as alcohol or drug addiction, psychiatric illness, and domestic violence, that require special attention ( ). Careful history and appropriate sensitivity are needed to address these life circumstances and optimize treatment of HIV. In general, initiation of antiretroviral therapy is recommended for all adults and adolescents with HIV, regardless of CD4+ lymphocyte counts ( ). This is a recent substantial change from previous guidelines, which recommended starting based on CD4+ level. Antiretroviral

2016 American College of Obstetricians and Gynecologists

88. Management of Vulvar Intraepithelial Neoplasia

genital warts and in women of all ages with suspected condyloma in whom topical therapies have failed. Treatment is recommended for all women with vulvar HSIL (VIN usual type). Because of the potential for occult invasion, wide local excision should be performed if cancer is suspected, even if biopsies show vulvar HSIL. When occult invasion is not a concern, vulvar HSIL (VIN usual type) can be treated with excision, laser ablation, or topical imiquimod (off-label use). Women with vulvar HSIL (VIN (...) lesions that rapidly change in color, border, or size. Expert opinion is divided regarding the need for biopsy of all warty lesions, but biopsy should be performed in postmenopausal women with apparent genital warts and in women of all ages with suspected condyloma in whom topical therapies have failed. Although information regarding the evaluation of women with immunocompromised conditions and HPV-related disease is limited, human immunodeficiency virus (HIV)-seropositive patients and patients

2016 American College of Obstetricians and Gynecologists

89. Childhood Laryngeal Tumors Treatment (PDQ®): Health Professional Version

common benign tumor is subglottic hemangioma.[ ] Malignant tumors, which are especially rare, may be associated with benign tumors such as polyps and papillomas.[ , ] Clinical Presentation These tumors may present with the following: Hoarseness. Difficulty swallowing. Enlargement of the lymph nodes of the neck. Treatment of Childhood Laryngeal Cancer Rhabdomyosarcoma is the most common pediatric malignant tumor of the larynx and is treated with chemotherapy and radiation therapy.[ ] (Refer to the PDQ (...) summary on for more information.) Squamous cell carcinoma of the larynx in children is managed in the same manner as it is in adults with carcinoma at this site, using surgery and radiation therapy.[ ] Laser surgery may be the initial treatment used for these lesions. (Refer to the PDQ summary on for more information about treatment of laryngeal cancer in adults.) Treatment Options Under Clinical Evaluation for Childhood Laryngeal Cancer Information about National Cancer Institute (NCI)–supported

2018 PDQ - NCI's Comprehensive Cancer Database

90. Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version

centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate in these trials is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with therapy that is currently accepted as standard. Most of the progress made in identifying curative therapy for childhood cancers has been achieved through clinical trials (...) . Information about ongoing clinical trials is available from the . Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[ ] Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment. (Refer to the PDQ summary on for specific information about the incidence, type, and monitoring of late

2018 PDQ - NCI's Comprehensive Cancer Database

91. Common conditions and diseases in HIV-positive men who have sex with men

? Body image is a concern for many men who have sex with men. Studies are needed to determine whether HIV-positive men who have sex with men experience issues with body image at a higher rate than their HIV-negative counterparts.(32) Given the high rates of sexually transmitted infections (STIs), substance use and mental health iissues experienced by people living with HIV, care providers should be aware of these risks and offer immunization, screening, treatment, counseling and other services (...) than HIV-positive men who have sex with men.(21) Matching of STI and AIDS databases in San Francisco has shown that people on highly active antiretroviral therapy (HAART) are more likely to develop another STI.(16) However, the differences in infection rates between HIV-positive and negative men who have sex with men may be due in part to a detection bias: HIV-positive men who have sex with men are generally under regular medical care so they are more likely to be screened for STIs. (15) Most STIs

2014 Ontario HIV Treatment Network

92. Anal Cancer Prevention (PDQ®): Health Professional Version

cell lesions, HPV-16 was present in about two-thirds and HPV-18 was present in about 5%.[ ] Because 85% of anal cancers have a squamous cell carcinoma histology or histologic variant,[ ] it is probable that elimination of oncogenic HPV infection would nearly eradicate anal cancer. HPVs are typically cleared rapidly in healthy individuals. Persistence of the oncogenic HPV strains is more likely in persons with compromised immune systems; therefore, risk of squamous cell anal cancer is much higher (...) ).[ ] Anal cancer risk is positively associated with severity of immunosuppression in HIV-positive and AIDS patients.[ ] When combined antiretroviral therapy (cART) became available in 1996, the incidence of anal cancer among these patients was expected to decrease. While decreases have been observed for other HIV-associated cancers, such trends have not been observed for anal cancer. It has been proposed that timing of cART treatment influences the risk of anal cancer, and that to be effective against

2017 PDQ - NCI's Comprehensive Cancer Database

93. Vaginal Cancer Treatment (PDQ®): Health Professional Version

is usually treated.[ ] Imiquimod cream 5%, an immune stimulant used to treat genital warts, is an additional topical therapy that has a reported complete clinical response rate of 50% to 86% in small case series of patients with multifocal high-grade HPV-associated VAIN 2 and 3.[ ] However, it is investigational, and it may have only short-lived efficacy.[ ] Current Clinical Trials Use our to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location (...) cases: 5,350. Deaths: 1,430. Carcinomas of the vagina are uncommon tumors comprising about 1% of the cancers that arise in the female genital system.[ , ] Early-stage tumors are often curable with local modality therapies, but there is no standard treatment of proven efficacy for metastatic disease. A large proportion (30%–50%) of women with vaginal carcinomas have had a previous hysterectomy for benign, pre-malignant, or malignant disease.[ , ] The American Joint Committee on Cancer (AJCC) staging

2017 PDQ - NCI's Comprehensive Cancer Database

94. CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. (PubMed)

the immunosuppression in large genital warts. Here, we further report that low-dose cyclophosphamide (CY), a conventional chemotherapy drug, can effectively prevent the recurrence of large CA in clinical patients after laser therapy. Surprisingly, although 9 out of 52 patients recur six weeks after the combination treatment, the re-administration of low-dose CY alone completely eliminates most recurred lesions. We provide evidence that low-dose CY not only depletes patients' Treg cells and enhances function of HPV (...) CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Condylomata acuminata (CA) caused by human papillomavirus (HPV) is a common sexually transmitted disease with half a million new cases diagnosed in the United States per year and the annual increase in incidence in China. Recurrence is a major challenge for CA treatment. Recently, we demonstrated that FOXP3(+) regulatory T (Treg) cells mediate

2010 Clinical immunology (Orlando, Fla.)

95. Management of Hepatitis C

. 104 Patients with HCV infection with mild immunodepression as a result of HIV also have more severe liver disease than those with HCV mono-infection. 105 There is a marked increase in liver related mortality in patients with CHC and HIV co-infection (RR 17.5). 106 Effective anti-HIV therapy and the associated immune recovery may limit HCV liver disease progression. 107 B The increased rate of progression to decompensated liver disease in patients with HCV and HIV co-infection should prompt early (...) aminotransferase 19 9.6 HIV co-infection 20 9.7 Co-infection with hepatitis A or B viruses 20 9.8 Iron status 20 9.9 HCV genotype 21 9.10 Cryoglobulinaemia 21 ContentsManagement of hepatitis C Management of Hepatitis C 10 Treatment of chronic hepatitis C 22 10.1 Antiviral therapy 22 10.2 Treatment variation by genotype 22 10.3 Patient subgroups 26 10.4 Factors influencing effectiveness 28 10.5 Contraindications 28 10.6 Management of adverse effects 30 10.7 Relapse or failed treatment 33 10.8 Monitoring

2013 SIGN

96. The FDA cracks down on bogus cancer “cures.” Will this be the last time this happens until after Trump?

in the wart of skin tags and moles then the salve will attack it and if not it will harm your skin.” “the herbs pull out the virus and cancer . . .” “It cleans cancer out of the body.” “It also helps with PMS and menopause.” “It pulls out bad cells, it helps draw out inflammation and pain.” Then there's : Liposomal Vitamin B17 Amygdalin “Laetrile (i.e. Vitamin B17) therapy is one of the most popular and best known alternative cancer treatments.” Laetrile? Seriously? That's so...1970s. Indeed, it's (...) , especially the FDA, for which the rationale is the fantasy that removing the "heavy hand of government" will unleash a flood of cures from the free market, I can't help but wonder if this sort of action is a dinosaur, at least for now. Be that as it may, as I mentioned yesterday, Stanislaw Burzynski is about as perfect example as I can recall of a major failure by the FDA. After all, he's been , most recently under the guise of experimental therapy, and neither the FDA nor the Texas Medical Board has

2017 Respectful Insolence

97. UK national guideline for the management of Genital Molluscum in adults

manifestations in paediatric HIV/AIDS patients in Mulago Hospital, Uganda. Afr Health Sci 2003; 3(2): 83-86. 75. Robinson MR, Udell IJ, Garber PF, et al. Molluscum contagiosum of the eyelids in patients with acquired immune deficiency syndrome. Ophthalmology 1992; 99(11): 1745-47. 76. Cursiefen C, Grunke M, Dechant C, et al. Multiple bilateral eyelid Molluscum Contagiosum lesions associated with TNFA-antibody and Methotrexate therapy. Am J Ophthamol 2002; 134(2): 270-71. 77. Margo C, Katz NN. Management (...) treatment with CO2 laser, trichloroacetic acid and pulsed dye laser. Lasers Surg Med 2000; 27(4), 291-94. 81. Calista D, Boschini A, Landi G. Resolution of disseminated molluscum contagiosum with Highly Active Anti-Retroviral Therapy (HAART) in patients with AIDS. Eur J Dermatol 1999; 9(3): 211-13. 82. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1(2): 107-15. 83. Ratnam

2014 British Association for Sexual Health and HIV

98. British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease)

participated in the advi- sory board of, and received travel expenses from LEO Pharma (nonspeci?c). C.A.M., A.J.B. and D.J.E. are members of the guideline development group. This is an updated guideline prepared for the British Association of Dermatologists (BAD) Clinical Standards Unit, made up of the Therapy & Guidelines (T&G) Subcom- mittee. Members of the Clinical Standards Unit are J.R. Hughes (Chairman T&G), A. Sahota, A.J. McDonagh, D.A. Buckley, I. Nasr, V.J. Swale, C.E. Duarte Williamson, P.M (...) intraepithelial neoplasia or perianal SCC in situ. 2.0 Stakeholder involvement and peer review The guideline development group consisted of consultant der- matologists. The draft document was circulated to the BAD membership, the British Dermatological Nursing Group (BDNG) and the Primary Care Dermatological Society (PCDS) for comments, and was peer reviewed by the Clinical Stan- dards Unit of the BAD (made up of the Therapy & Guidelines Subcommittee) prior to publication. 3.0 Methodology This set

2014 British Association of Dermatologists

99. Complementary, Alternative and Traditional Medicine in HIV Care

: Allopathic, com- plementary, and alternative treat- ments. Journal of Psychosomatic Research 2004;57(4):339-51. 14) Owen-Smith A, McCarty F, Hanker- son-Dyson D, DiClemente R. Preva- lence and predictors of comple- mentary and alternative medicine use in African-Americans with ac- quired immune deficiency syn- drome. Focus on Alternative Com- plementary Therapies 2012;17 (1):33-42. 15) Huber JT, Gullion JS. Complemen- tary and alternative medicine as represented in the HIV/AIDS body of knowledge (...) for the effectiveness of complementary, alternative and/or traditional medicine use among people living with HIV? 2. Are complementary, alternative and/or traditional medicines being used to complement or replace antiretroviral treatment? 3. Do complementary, alternative and/or traditional medicines interact with or counteract antiretroviral therapies? 4. With what frequency are complementary, alternative and/or traditional medicines being used by African, Caribbean and Black populations in Canada to treat HIV? 5

2013 Ontario HIV Treatment Network

100. Management of molluscum contagiosum

. 36,51,56,57 Severe molluscum infections were also common in HIV patients in the pre-highly active antiretroviral therapy (HAART) era, 58,59 estimated to a?ect 5–18% of positive individuals. 60–63 Extensive disease usually occurs in the setting of late HIV, with CD4 counts sig- ni?cantly under 200 and concurrent illnesses related to advanced HIV infection. 45,61,64–72 Extensive molluscum may be the ?rst indication of HIV disease. 45 Lesionsoccurcommonlyonthefaceandneck, 49,73 but can sometimes a?ect (...) the genital regions, indicating both venereal and non-venereal spread in this scenario. 45 Particularly in immunocompromise, molluscum lesions cana?ecttheeyelids 74–76 andcausechronicconjunctivitis duetoaforeignbody-typereaction. 14,75,77–79 Molluscum infectioncanbeparticularlydi?culttotreatinlate-stage HIV using conventional means, 62,80 though usually responding to HIV antiretroviral treatment (ARV) initi- ation. 81 However, an immune reconstitution in?amma- tory syndrome (IRIS) reaction to molluscum

2014 British Association for Sexual Health and HIV

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>